Related references
Note: Only part of the references are listed.Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases
Taku Fukuzawa et al.
SCIENTIFIC REPORTS (2017)
Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics
Danlin Yang et al.
ANALYTICAL BIOCHEMISTRY (2016)
PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody-antigen binding model
Kenta Haraya et al.
DRUG METABOLISM AND PHARMACOKINETICS (2016)
De novo isolation of antibodies with pH-dependent binding properties
Pauline Bonvin et al.
MABS (2015)
Fully human monoclonal antibocy inibitors of the neonatal Fc receptor reduce circulating IgG in non-human primates
Andrew E. Nixon et al.
FRONTIERS IN IMMUNOLOGY (2015)
pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling
M. Jack Borrok et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Mechanistic Investigation of the Preclinical Pharmacokinetics and Interspecies Scaling of PF-05231023, a Fibroblast Growth Factor 21-Antibody Protein Conjugate
Craig Giragossian et al.
DRUG METABOLISM AND DISPOSITION (2015)
Anti-PCSK9 Antibody Pharmacokinetics and Low-Density Lipoprotein-Cholesterol Pharmacodynamics in Nonhuman Primates Are Antigen Affinity-Dependent and Exhibit Limited Sensitivity to Neonatal Fc Receptor-Binding Enhancement
Kirk R. Henne et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
pH-dependent antigen-binding antibodies as a novel therapeutic modality
T. Igawa et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2014)
Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery
E-Chiang Lee et al.
NATURE BIOTECHNOLOGY (2014)
A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics
Peter Hodsman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics
Siva Charan Devanaboyina et al.
MABS (2013)
Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo
Tomoyuki Igawa et al.
PLOS ONE (2013)
Evaluation of a Catenary PBPK Model for Predicting the In Vivo Disposition of mAbs Engineered for High-Affinity Binding to FcRn
Yang Chen et al.
AAPS JOURNAL (2012)
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9
Javier Chaparro-Riggers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human
Dhaval K. Shah et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma
Jacek R. Wisniewski et al.
MOLECULAR SYSTEMS BIOLOGY (2012)
Bioanalytical Approaches to Quantify Total and Free Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development
Jean W. Lee et al.
AAPS JOURNAL (2011)
Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys
Jim J. Xiao et al.
AAPS JOURNAL (2010)
Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets
Jasmine P. Davda et al.
MABS (2010)
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Tomoyuki Igawa et al.
NATURE BIOTECHNOLOGY (2010)
Therapeutic antibodies for autoimmunity and inflammation
Andrew C. Chan et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma
Philip J. Lowe et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Paul Ehrlich's magic bullet concept: 100 years of progress
Klaus Strebhardt et al.
NATURE REVIEWS CANCER (2008)
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice
Amit Garg et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria
Karolina M. Zareba
DRUGS OF TODAY (2007)
Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy
Prashant Prabhat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)
William F. Dall'Acqua et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Elimination mechanisms of therapeutic monoclonal antibodies
MA Tabrizi et al.
DRUG DISCOVERY TODAY (2006)
Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn
RJ Ober et al.
JOURNAL OF IMMUNOLOGY (2004)
Exocytosis of IgG as mediated by the receptor, FcRn: An analysis at the single-molecule level
RJ Ober et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Share Paper
